The Gee$e.

[di4]

4/18/2007
Ken Coleman’s readers are up 4,000% on UPL, 2,000% on TRLG, 1,000% on HL, 853% on TALK.

Tiny microcap makes giant leap in the race to save half a billion lives!

A new disease is sweeping America, more deadly than AIDS, more silent than heart disease, and so new that it didn’t even have a name until 1994.

Tiny HepaLife Technologies (HPLF) just passed
an important milestone in a breakthrough
treatment that could give you a potential 500%
in a few short weeks. Here’s why…
To get the
full report,
click here.

I specialize in finding stocks that are ready to give investors a big payday. One of my recent discoveries shot up 37% on the day I recommended it.

That was just a few months ago. It went on to give 165% profits in the first nine days after my recommendation.

Another pick only three months earlier gave my readers 528% in 90 days.

HPLF could be your next big winner, giving you a chance for 500% gains practically overnight .

The reason is because HepaLife has a new discovery that has worldwide importance. The company’s product in development could potentially be the difference between life or death for victims of a deadly new disease that attacks its victims’ livers.

You can read my full report on this deadly new disease, and why you could make a quick 500% on HepaLife’s important discovery, in a FREE special report that I prepared for my subscribers.

You’ll find the full report at:
http://theinvestmenttracker.com/report/april-report-hplf14.html .
But don’t delay – only early investors enjoy big gains.




To get the
full report,
click here. Note: To ease your concerns about potential download viruses, this is a website link, not a PDF download.


If your email client has disabled the clickable links, copy and paste this link into a browser:
http://theinvestmenttracker.com/report/april-report-hplf14.html



Copyright ©2007 - The Investment Tracker. All Rights Reserved.



Disclaimer: Kenneth Coleman's Investment Tracker is an independent paid circulation newsletter. This online report is an advertisement for subscriptions. The Investment Tracker received 6,250 dollars with respect to the writing of this special report from HepaLife Technologies, Inc. ("HepaLife"), however, the Investment Tracker expects to generate new subscriber revenue, the amount of which is unknown at this time, to its newsletter through the distribution of this special report. Compensation associated with distribution to possible new subscribers in the amount of 16,200 dollars was paid for HepaLife as an effort to build investor awareness for HepaLife. This publication does not provide an analysis of a company's financial position and is not an offer to buy or sell securities. HepaLife's financial position and all information should be verified with the company. The Investment Tracker presents information in this report believed to be reliable, but its accuracy cannot be guaranteed. Past performance does not guarantee future results. The information contained herein contains forward-looking statements and information within the meaning of Section 27A of the Securities Act of 1993 and Section 21E of the Securities Exchange Act of 1934. In accordance with safe harbor provisions of the Private Securities Litigation Reform Act of 1995, the statements contained herein that look forward in time, which include other than historical information, involve risks and uncertainties that may affect actual results of operations. The Investment Tracker makes no commitment to publicly release the results of any revisions to these projected statements that may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a full copy of this disclaimer, please click here: Full Disclaimer.



--------------------------------------------------------------------------------
[e-mail]: We do not endorse the foregoing, and we assume no responsibility for the purchase and/or use thereof. InvestmentHouse.com has no affiliation and is not recommending the mentioned stock. We have not independently confirmed the accuracy, correctness, or truthfulness of the statements and opinions that the advertiser has expressed above or in any related reports. We encourage you to verify all claims contained in the above advertisement and to investigate the company or investment opportunity. Our very limited research, which should not be relied on, has found that the above-mentioned company's independent auditors has issued a going concern opinion. You are hereby advised that Online Investment Services, LP ("OIS") (owner of InvestmentHouse.com) is receiving a cash fee of thirteen thousand five hundred dollars for the distribution of this email. The company is not affiliated with OIS. Please read the full disclosure here. You may review our Privacy Policy. If you no longer wish to receive this newsletter, please unsubscribe now.
1153 Bergen Pkwy, Suite M502, Evergreen,